Advertisement

Breast Cancer Research and Treatment

, Volume 141, Issue 1, pp 67–78 | Cite as

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

  • Claudia Fumarola
  • Cristina Caffarra
  • Silvia La Monica
  • Maricla Galetti
  • Roberta R. Alfieri
  • Andrea Cavazzoni
  • Elena Galvani
  • Daniele Generali
  • Pier Giorgio Petronini
  • Mara A. Bonelli
Preclinical Study

Abstract

In this study, we investigated the effects and the underlying molecular mechanisms of the multi-kinase inhibitor sorafenib in a panel of breast cancer cell lines. Sorafenib inhibited cell proliferation and induced apoptosis through the mitochondrial pathway. These effects were neither correlated with modulation of MAPK and AKT pathways nor dependent on the ERα status. Sorafenib promoted an early perturbation of mitochondrial function, inducing a deep depolarization of mitochondrial membrane, associated with drop of intracellular ATP levels and increase of ROS generation. As a response to this stress condition, the energy sensor AMPK was rapidly activated in all the cell lines analyzed. In MCF-7 and SKBR3 cells, AMPK enhanced glucose uptake by up-regulating the expression of GLUT-1 glucose transporter, as also demonstrated by AMPKα1 RNA interference, and stimulated aerobic glycolysis thus increasing lactate production. Moreover, the GLUT-1 inhibitor fasentin blocked sorafenib-induced glucose uptake and potentiated its cytotoxic activity in SKBR3 cells. Persistent activation of AMPK by sorafenib finally led to the impairment of glucose metabolism both in MCF-7 and SKBR3 cells as well as in the highly glycolytic MDA-MB-231 cells, resulting in cell death. This previously unrecognized long-term effect of sorafenib was mediated by AMPK-dependent inhibition of the mTORC1 pathway. Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake. The key role of AMPK-dependent inhibition of mTORC1 in sorafenib mechanisms of action was confirmed by AMPKα1 silencing, which restored mTORC1 activity conferring a significant protection from cell death. This study provides insights into the molecular mechanisms driving sorafenib anti-tumoral activity in breast cancer, and supports the need for going on with clinical trials aimed at proving the efficacy of sorafenib for breast cancer treatment.

Keywords

Sorafenib Breast cancer mTORC1 AMPK Energy metabolism 

Notes

Acknowledgments

We thank Bayer HealthCare Pharmaceuticals for providing sorafenib and A.VO.PRO.RI.T., Parma, Italy for its support.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24):7271–7278PubMedCrossRefGoogle Scholar
  2. 2.
    Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R (2009) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14(1):95–100PubMedCrossRefGoogle Scholar
  3. 3.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287):431–435PubMedCrossRefGoogle Scholar
  4. 4.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287):427–430PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109PubMedCrossRefGoogle Scholar
  6. 6.
    Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM (2007) Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282(40):29230–29240PubMedCrossRefGoogle Scholar
  7. 7.
    Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG (2010) Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 124(1):79–88PubMedCrossRefGoogle Scholar
  8. 8.
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13(8B):2673–2683PubMedCrossRefGoogle Scholar
  9. 9.
    Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24(46):6861–6869PubMedCrossRefGoogle Scholar
  10. 10.
    Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC (2008) Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 68(15):6109–6117PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Fiume L, Manerba M, Vettraino M, Di Stefano G (2011) Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. Eur J Pharmacol 670(1):39–43PubMedCrossRefGoogle Scholar
  12. 12.
    Bull VH, Rajalingam K, Thiede B (2012) Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J Proteome Res 11(3):1609–1620PubMedCrossRefGoogle Scholar
  13. 13.
    Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gomez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Duran MA, Hoff PM, Espie M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30(13):1484–1491PubMedCrossRefGoogle Scholar
  14. 14.
    Hudis C, Tauer KW, Hermann G, et al (2011) Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol 29(suppl; abstr 1009)Google Scholar
  15. 15.
    Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L (2013) A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 49(2):312–322PubMedCrossRefGoogle Scholar
  16. 16.
    Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL, Creswell K, Novielli A, Slack R (2011) Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 125(1):137–143PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78(5):460–468PubMedCrossRefGoogle Scholar
  18. 18.
    Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG (2005) Cell size reduction induced by inhibition of the mTOR/S6 K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 12(10):1344–1357PubMedCrossRefGoogle Scholar
  19. 19.
    Zhao Y, Wieman HL, Jacobs SR, Rathmell JC (2008) Mechanisms and methods in glucose metabolism and cell death. Methods Enzymol 442:439–457PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Ashcroft SJ, Weerasinghe LC, Bassett JM, Randle PJ (1972) The pentose cycle and insulin release in mouse pancreatic islets. Biochem J 126(3):525–532PubMedCentralPubMedGoogle Scholar
  21. 21.
    Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q (2011) Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs 22(1):79–88PubMedCrossRefGoogle Scholar
  22. 22.
    Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA (2008) Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 106(1):153–161PubMedCrossRefGoogle Scholar
  23. 23.
    Coriat R, Nicco C, Chereau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 11(10):2284–2293PubMedCrossRefGoogle Scholar
  24. 24.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F (2011) HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 130(1):29–40PubMedCrossRefGoogle Scholar
  25. 25.
    Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T (2012) Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs 23(5):525–533PubMedCrossRefGoogle Scholar
  26. 26.
    Tran MA, Smith CD, Kester M, Robertson GP (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 14(11):3571–3581PubMedCrossRefGoogle Scholar
  27. 27.
    Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140PubMedCrossRefGoogle Scholar
  28. 28.
    O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500–1508PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J (2012) PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777–1789PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27(15):5499–5513PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Sanchez-Hernandez I, Baquero P, Calleros L, Chiloeches A (2012) Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett 314(2):244–255PubMedCrossRefGoogle Scholar
  32. 32.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W (2009) Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220(1):214–221PubMedCrossRefGoogle Scholar
  33. 33.
    Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X (2010) The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46(4):836–850PubMedCrossRefGoogle Scholar
  34. 34.
    Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G (2012) Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 11(15):2843–2855PubMedCrossRefGoogle Scholar
  35. 35.
    Cardaci S, Filomeni G, Ciriolo MR (2012) Redox implications of AMPK-mediated signal transduction beyond energetic clues. J Cell Sci 125(Pt 9):2115–2125PubMedCrossRefGoogle Scholar
  36. 36.
    Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D, Hue L (2000) Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10(20):1247–1255PubMedCrossRefGoogle Scholar
  37. 37.
    Almeida A, Moncada S, Bolanos JP (2004) Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol 6(1):45–51PubMedCrossRefGoogle Scholar
  38. 38.
    Hao WS, Chang CPB, Tsao CC, Xu J (2010) Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem 285(17):12647–12654PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Wu SB, Wei YH (2012) AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim Biophys Acta 1822(2):233–247PubMedCrossRefGoogle Scholar
  40. 40.
    Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D (2004) Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 279(46):47726–47731PubMedCrossRefGoogle Scholar
  41. 41.
    Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39(2):171–183PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18(6):598–608PubMedCrossRefGoogle Scholar
  43. 43.
    Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, Liu SH, Cheng AL (2013) Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 108(1):72–81PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Claudia Fumarola
    • 1
  • Cristina Caffarra
    • 1
  • Silvia La Monica
    • 1
  • Maricla Galetti
    • 1
  • Roberta R. Alfieri
    • 1
  • Andrea Cavazzoni
    • 1
  • Elena Galvani
    • 1
  • Daniele Generali
    • 2
    • 3
  • Pier Giorgio Petronini
    • 1
  • Mara A. Bonelli
    • 1
  1. 1.Department of Clinical and Experimental MedicineUniversity of ParmaParmaItaly
  2. 2.Unità di Patologia Mammaria-Breast Cancer UnitIstituti Ospitalieri di CremonaCremonaItaly
  3. 3.Centro di Medicina MolecolareIstituti Ospitalieri di CremonaCremonaItaly

Personalised recommendations